Anktiva is the first FDA-approved immunotherapy that activates the immune system to treat BCG-unresponsive non-muscle invasive bladder cancer (CIS), offering some patients a lasting complete response.
To Get Full Access :
To Get Full Access :
Anktiva is the first FDA-approved immunotherapy that activates the immune system to treat BCG-unresponsive non-muscle invasive bladder cancer (CIS), offering some patients a lasting complete response.
Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
